243 related articles for article (PubMed ID: 19797556)
21. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
Yarom N; Yahalom R; Shoshani Y; Hamed W; Regev E; Elad S
Osteoporos Int; 2007 Oct; 18(10):1363-70. PubMed ID: 17598065
[TBL] [Abstract][Full Text] [Related]
22. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw.
Wilde F; Heufelder M; Winter K; Hendricks J; Frerich B; Schramm A; Hemprich A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Feb; 111(2):153-63. PubMed ID: 20674411
[TBL] [Abstract][Full Text] [Related]
23. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome.
Van den Wyngaert T; Claeys T; Huizing MT; Vermorken JB; Fossion E
Ann Oncol; 2009 Feb; 20(2):331-6. PubMed ID: 18953067
[TBL] [Abstract][Full Text] [Related]
24. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors.
Adornato MC; Morcos I; Rozanski J
J Am Dent Assoc; 2007 Jul; 138(7):971-7. PubMed ID: 17606496
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate treatment as a cause of jaw osteonecrosis.
Kanat O; Ozet A; Ataergin S; Kuzhan O; Arpaci F; Ozturk B; Komurcu S; Ozturk M
Oral Dis; 2007 May; 13(3):346-7. PubMed ID: 17448221
[No Abstract] [Full Text] [Related]
26. [Osteonecrosis of the jaw developing during bisphosphonate treatment].
Udvardy E; Redl P; Márton I
Magy Onkol; 2008 Mar; 52(1):81-7. PubMed ID: 18403302
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
28. [Bisphosphonate-associated osteonecrosis of the jaw].
Abu-Id MH; Açil Y; Gottschalk J; Kreusch T
Mund Kiefer Gesichtschir; 2006 Mar; 10(2):73-81. PubMed ID: 16456688
[TBL] [Abstract][Full Text] [Related]
29. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
30. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
31. Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan.
Yamazaki T; Yamori M; Yamamoto K; Saito K; Asai K; Sumi E; Goto K; Takahashi K; Nakayama T; Bessho K
Bone; 2012 Nov; 51(5):882-7. PubMed ID: 22917933
[TBL] [Abstract][Full Text] [Related]
32. [Osteonecrosis of the jaw].
Drozdzowska B
Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
[TBL] [Abstract][Full Text] [Related]
33. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
Van Poznak C
Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
[TBL] [Abstract][Full Text] [Related]
34. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.
Sedghizadeh PP; Stanley K; Caligiuri M; Hofkes S; Lowry B; Shuler CF
J Am Dent Assoc; 2009 Jan; 140(1):61-6. PubMed ID: 19119168
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people.
Cartsos VM; Zhu S; Zavras AI
J Am Dent Assoc; 2008 Jan; 139(1):23-30. PubMed ID: 18167381
[TBL] [Abstract][Full Text] [Related]
36. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
[TBL] [Abstract][Full Text] [Related]
37. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
38. Intravenous bisphosphonate-associated osteonecrosis of the jaw.
Statz TA; Guthmiller JM; Humbert LA; Johnson GK
J Periodontol; 2007 Nov; 78(11):2203-8. PubMed ID: 17970689
[TBL] [Abstract][Full Text] [Related]
39. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
40. [Bisphosphonates and osteonecrosis of the jaws].
Urade M
Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
